Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Signals Need For Private Investment To Support Its Healthcare Reforms; Private Insurance Options Likely To Widen

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China recently lifted a ban on foreign investment in medical institutes to support its $124 billion healthcare reforms and the establishment of wholly foreign-owned hospitals and clinics. The move by the Chinese government is being read as a signal that China may open more of the country's healthcare industry to foreign investment

You may also be interested in...



Shanghai Free Trade Zone Will Impact Foreign Investment In Health Care Sectors

The Shanghai Free Trade Zone creates a shortcut for foreign investors to enter China and also opens a gate for domestic companies to invest in foreign assets, but several restrictions on the health care sector remain.

Insider Analysis From L.E.K. Consulting On The Private Health Insurance Market In China: Business As Usual Or Breakthrough Imminent?

In the midst of China’s massive healthcare reforms, including focus on expanding health insurance coverage, one area has not received much attention from policy makers and market participants until recently – the private health insurance market.

A Closer Look: World Bank’s China 2030 Report Has Implications For The Healthcare Industry

A report by the World Bank encourages China to hasten a shift to non-state-owned medical services.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC073815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel